Quick Answer — What is Selank?
Selank is a 7-amino-acid synthetic heptapeptide developed at the Russian Academy of Sciences as an analog of the endogenous immunomodulatory peptide tuftsin. In published research it acts as an anxiolytic nootropic, modulating GABAergic, serotonergic, and enkephalin signalling and upregulating BDNF expression without the sedation or dependence profile of benzodiazepines. Supplied in 5 mg and 10 mg lyophilized vials for laboratory research use only.
📦 Κάθε παραγγελία καλύπτεται από την Πολιτική Εγγύησης Επαναποστολής — εάν το δέμα σας δεν φτάσει εντός 20 εργάσιμων ημερών, το επαναποστέλλουμε.
| Specification | Detail |
|---|---|
| CAS Number | 129954-34-3 |
| Molecular Formula | C33H57N11O9 |
| Molecular Weight | 751.88 Da |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2 (TKPRPGP-NH2, 7 amino acids; C-terminally amidated tuftsin analog) |
| Form | Lyophilized powder (white to off-white) |
| Purity | ≥99% (HPLC verified, COA on request) |
| Storage | Lyophilized: 2–8 °C (refrigerator) for working stock; −20 °C for long-term storage of unopened vials. Reconstituted: 2–8 °C, use within ~30 days. Protect from light. Do not freeze–thaw the reconstituted solution. |
| Solubility | Bacteriostatic water (recommended) or sterile water for shorter use windows. Compatible with intranasal vehicle research formulations. |
| Research Use | For laboratory research use only. Not for human or veterinary diagnostic or therapeutic use. |
What Is Selank?
Selank is a synthetic heptapeptide developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences, the same laboratory that developed Semax. It is structurally an analog of the endogenous immunomodulatory tetrapeptide tuftsin (TKPR), extended at the C-terminus with a Pro-Gly-Pro tail that confers proteolytic stability and an amidated C-terminus. The tail extension dramatically extends plasma half-life relative to native tuftsin, which is degraded within minutes, while preserving the immunomodulatory activity of the parent peptide.
Selank’s well-characterised sequence is TKPRPGP-NH2, molecular weight 751.88 Da, empirical formula C33H57N11O9. It is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. In Russia, Selank is approved as a prescription anxiolytic under the name Selank (intranasal spray); outside the post-Soviet bloc it is not approved by the FDA, EMA, MHRA, or any other major regulator. The research-grade Selank sold here is supplied for laboratory research use only and is not approved for human or veterinary administration. For sister-peptide research, see our Semax product page.
Mechanism of Action — GABAergic, Serotonergic, and BDNF Pathways
What makes Selank distinctive among anxiolytic research compounds is its multi-pathway neuromodulatory profile without direct receptor binding to the GABAA benzodiazepine site — each contributing to the observed anxiolytic and nootropic phenotype in published research:
- GABAergic modulation without benzodiazepine-site binding — Selank potentiates GABA-mediated inhibition through allosteric effects distinct from the benzodiazepine binding pocket. In rodent research models it raises seizure threshold and produces anxiolysis on elevated-plus-maze and open-field tests, but without the sedation, motor coordination loss, dependence liability, or rebound anxiety seen with diazepam. This distinct mode of GABA modulation is the most-studied aspect of Selank’s pharmacology.
- Serotonergic and enkephalinergic signalling — Published research has documented increased serotonin metabolism (5-HIAA / 5-HT ratio) in cortical and limbic regions following Selank administration in rodents, alongside upregulation of enkephalin gene expression. The combined serotonergic and enkephalinergic signal is thought to contribute to mood-modulatory and stress-resilience effects in chronic-stress research models.
- BDNF expression and neuroplasticity — Selank raises brain-derived neurotrophic factor (BDNF) expression in the hippocampus and prefrontal cortex in published research, a mechanism increasingly recognised as central to the long-term effects of mood-modulatory compounds. BDNF upregulation also underpins Selank’s nootropic profile — improved memory consolidation and learning performance in rodent maze tasks.
Selank is intranasally bioavailable (one of the very few peptides with documented mucosal absorption), which is the primary research route in published Russian and Eastern European studies. The intranasal route bypasses first-pass metabolism and delivers peptide directly across the cribriform plate into central compartments, producing CNS effects within minutes of administration. Subcutaneous administration is also documented in preclinical research and produces a similar pharmacological profile with slightly slower onset.
Published Research Applications
Selank is used in laboratory research contexts that investigate:
- Anxiolytic pharmacology — elevated-plus-maze, open-field, social-interaction tests in rodent models of generalised anxiety; comparative arms against benzodiazepines (diazepam) and SSRIs (Kozlovskaya et al., Eksp Klin Farmakol; Inozemtsev et al., Bull Exp Biol Med)
- Stress resilience and HPA-axis research — chronic mild stress, restraint stress, and learned-helplessness models; cortisol and ACTH dynamics
- BDNF and neuroplasticity research — hippocampal and prefrontal BDNF expression, dendritic spine morphology, long-term potentiation electrophysiology
- Cognitive and memory research — Morris water maze, novel object recognition, passive avoidance; nootropic effects independent of anxiolysis
- Immunomodulation — Selank inherits tuftsin’s immunomodulatory activity, with documented effects on cytokine balance (TNF-α, IL-6, IFN-γ) and macrophage function in published research
- Comparative research vs benzodiazepines — head-to-head with diazepam, alprazolam, and phenazepam on anxiolytic efficacy, dependence liability, and rebound; Selank’s clean withdrawal profile is one of the most-cited findings in the Russian literature
- Sister-peptide research — benchmarking against Semax (a sister heptapeptide from the same laboratory) for nootropic and neuroprotective effects.
For broader context on small-peptide neuromodulation and nootropic research, see Semax as the canonical Russian-developed nootropic comparator, Epitalon for pineal-peptide longevity research, and BPC-157 for the parallel small-peptide healing-research compound. Browse the full research peptides catalog for related compounds.
Available Strengths and Concentrations
MedsBase stocks Selank in two lyophilized vial sizes calibrated to typical research protocol lengths. Each strength is available in 10-vial or 20-vial pack formats with full reconstitution guidance:
| Vial Strength | Typical Research Use Case | Pack Sizes |
|---|---|---|
| 5 mg | Short research protocols, pilot dosing, intranasal-vehicle formulation studies | 10 or 20 vials |
| 10 mg | Standard research strength, extended protocols, lowest per-mg cost | 10 or 20 vials |
Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when researchers want to minimise injection or intranasal-delivery volume in rodent protocols.
How It Compares — Selank vs Semax
Selank and Semax are sister peptides developed at the same Russian laboratory (Institute of Molecular Genetics, Russian Academy of Sciences) and are often compared in research because they share heptapeptide architecture, intranasal bioavailability, and Russian regulatory history but differ substantially in primary pharmacological action. Selank is the canonical anxiolytic of the pair; Semax is the canonical nootropic/neuroprotective.
| Criterion | Selank | Semax |
|---|---|---|
| Length | 7 amino acids (heptapeptide) | 7 amino acids (heptapeptide) |
| Parent peptide | Tuftsin (TKPR) | ACTH(4-10) fragment |
| Primary mechanism | GABA modulation, BDNF, enkephalin | BDNF, melanocortin receptors, dopamine |
| Primary research signal | Anxiolytic, stress resilience | Nootropic, neuroprotective, focus |
| Typical research dose (intranasal) | 300–900 mcg/day | 200–1,000 mcg/day |
| Russian clinical use | Approved anxiolytic (intranasal) | Approved nootropic / stroke recovery (intranasal) |
| Stacking in research | Frequently combined with Semax for complementary anxiolytic+nootropic effect | Frequently combined with Selank |
Because the two peptides act on complementary axes — Selank on GABA/anxiolytic, Semax on melanocortin/dopaminergic/nootropic — they are frequently co-administered in research protocols investigating cognitive performance under stress, where both arms (calm and focus) contribute to the studied phenotype.
Storage and Reconstitution
Before reconstitution: store lyophilized vials refrigerated at 2–8 °C in original packaging for short-term working stock. For unopened long-term storage, freeze at −20 °C. Lyophilized Selank is stable under refrigeration for up to 24 months and at −20 °C for up to 36 months. Avoid freeze-thaw cycles on the lyophilized powder.
Reconstitution procedure: inject bacteriostatic water down the side wall of the peptide vial (not directly onto the lyophilized cake). For a 5 mg vial, 1.0 mL of bacteriostatic water yields a 5 mg/mL working concentration; 0.1 mL delivers a 500 mcg research dose. Swirl gently — do δεν shake — and allow 2–5 minutes for full dissolution. A correctly reconstituted solution should be clear and colourless. For intranasal-vehicle research formulations, the reconstituted solution can be transferred to a calibrated nasal-spray bottle delivering ~100 μL per pump.
After reconstitution: store refrigerated at 2–8 °C and use within 30 days for optimal stability. Do not freeze the reconstituted solution — freeze-thaw cycles degrade peptide integrity. Discard any vial showing cloudiness, precipitate, or discolouration.
Συχνές Ερωτήσεις
What is Selank used for in research?
Selank is used in laboratory research investigating anxiolytic pharmacology, stress resilience, BDNF and neuroplasticity, cognitive performance, immunomodulation, and head-to-head comparison against benzodiazepines. It is the most-cited Russian-developed anxiolytic peptide in the literature. The research-grade Selank sold here is δεν FDA-approved and is supplied strictly for laboratory research use only.
How is Selank different from Semax?
Both are 7-amino-acid heptapeptides from the same Russian laboratory and share intranasal bioavailability, but their mechanisms differ. Selank is derived from the immunomodulatory peptide tuftsin and acts predominantly via GABAergic, enkephalinergic, and BDNF pathways — canonical research arm: anxiolysis. Semax is derived from ACTH(4-10) and acts via melanocortin receptors, BDNF, and dopaminergic modulation — canonical research arm: nootropic and neuroprotection. The two are frequently co-administered in research because the effects are complementary rather than overlapping.
What is the typical Selank research dose?
Published Russian protocols typically use 300–900 mcg per day administered intranasally in 3 divided doses, or equivalent subcutaneous doses. A 5 mg vial reconstituted with 1.0 mL bacteriostatic water yields 5 mg/mL — 0.1 mL equals 500 mcg, a typical single-dose research aliquot.
Is Selank FDA approved?
No. Selank is not approved by the FDA, EMA, MHRA, or any major Western regulator. It is approved in Russia as a prescription anxiolytic under the brand name Selank (intranasal spray, ZAO Pharm-Sintez). All Selank sold by research-use-only suppliers outside Russia is for laboratory investigation and should not be administered to humans.
How should Selank be stored?
Lyophilized vials: refrigerated at 2–8 °C for short-term working stock, or −20 °C for long-term storage of unopened vials. Reconstituted solution: refrigerated at 2–8 °C, use within 30 days. Do not freeze reconstituted solution — freeze-thaw cycles degrade the peptide. Protect from direct light at all times.
How do I reconstitute Selank?
Follow the reconstitution procedure above. Add bacteriostatic water down the side wall of the vial (not onto the lyophilized cake), swirl gently, and allow 2–5 minutes for full dissolution. Do δεν shake the vial. A correctly reconstituted solution is clear and colourless. For a 5 mg vial + 1.0 mL diluent, the working concentration is 5 mg/mL.
What strengths does MedsBase stock?
MedsBase carries Selank in 5 mg and 10 mg lyophilized vials. Each strength is available in 10-vial or 20-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request.
Can Selank be administered intranasally in research?
Yes — intranasal administration is the primary research route in Russian and Eastern European published studies. Selank is one of the few peptides with documented intranasal bioavailability, attributable to its small size (7 aa, ~752 Da) and amidated C-terminus. The route bypasses first-pass metabolism and delivers peptide across the cribriform plate into central compartments within minutes of administration. Subcutaneous and intramuscular routes also work in preclinical models.
Can Selank and Semax be stacked in research?
Yes. Selank and Semax are frequently co-administered in published research because their mechanisms are complementary. Selank provides anxiolytic and stress-buffering effects via GABA/enkephalin/BDNF pathways; Semax provides nootropic and neuroprotective effects via melanocortin/dopaminergic/BDNF pathways. The combination is particularly studied in research models of cognitive performance under stress.
Does Selank cause side effects in research?
Published preclinical and Russian clinical research has reported a notably clean safety profile at typical research doses, with no consistent sedation, motor-coordination effects, dependence liability, or rebound on discontinuation — in clear contrast to benzodiazepine comparator arms. Long-term safety data outside Russia is limited because the peptide has not undergone Western regulatory review.
What is the half-life of Selank?
In preclinical research, Selank has an estimated plasma half-life of approximately 15–30 minutes following intranasal administration, far longer than the parent peptide tuftsin (under 5 minutes). The short plasma half-life is offset by central-compartment accumulation following intranasal delivery and downstream effects on BDNF and gene expression that persist beyond plasma clearance.
How long does Selank take to show effects in preclinical research?
Acute anxiolytic effects on elevated-plus-maze and open-field tests are detectable within 30–60 minutes of intranasal administration. BDNF and gene-expression effects accumulate over 7–14 days of regular dosing and underpin the longer-term mood-modulatory and nootropic phenotype observed in chronic-stress research models.
Can I order Selank for international shipping?
Yes. MedsBase ships Selank worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking and are covered by our Πολιτική Εγγύησης Επαναποστολής.
Other Peptides for Nootropic, Neuroprotective, and Cognitive Research
- Semax — Sister heptapeptide from the same Russian laboratory — nootropic and neuroprotective research
- Epitalon — AEDG pineal tetrapeptide — longevity and circadian research
- BPC-157 — Body Protection Compound — healing and tissue-recovery research
- KPV — Small immunomodulatory tripeptide — inflammation and barrier research
- Ανταμάξ — Heptapeptide nootropic research compound
Further Reading
📖 Explore small-peptide nootropic research
Browse the full research peptides catalog, with related compounds including Semax for melanocortin-axis nootropic research, Epitalon for pineal-peptide longevity research, and Ανταμάξ for sister heptapeptide cognitive research.



























Κριτικές
Δεν υπάρχουν ακόμη κριτικές